Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 DSM Biologics, Argenes Sign Bio-Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News

DSM Biologics, Argenes Sign Bio-Agreement

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

DSM Biologics and Argenes, Inc., headquartered in Tokyo, Japan, have signed a biopharmaceutical manufacturing agreement. Under the terms of the agreement, DSM will provide Argenes with full process development services, analytical development services and manufacturing batches for Argenes’ Anti-Fas IgM monoclonal antibody. The services will be provided out of DSM Biologics’ FDA-approved manufacturing facility in Groningen, The Netherlands. Argenes’ Anti-FAS IgM monoclonal antibody is being developed as an anti-rheumatic agent.

“The agreement is a further reinforcement of the strong and mutually beneficial relationship between Argenes and DSM Biologics. We gladly entrust DSM with the execution of this agreement that is crucial for the success of our Anti-Fas IgM monoclonal antibody,” said Kamishohara, president and chief executive officer of Argenes.

“DSM Biologics is very pleased to be involved in this exciting project. The agreement is a clear recognition of the value that DSM Biologics has brought, and will continue to bring to Argenes, an important client for DSM Biologics,” said Terry Novak, chief marketing officer of DSM Biologics.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics